Non-compliance: the Achilles' heel of anti-fracture efficacy

By Seeman E.   Compston J.   Adachi J.   Brandi M.   Cooper C.   Dawson-Hughes B.   Jönsson B.   Pols H.   Cramer J.  

Osteoporosis International, Vol. 18, Iss. 6, 2007-06 ,pp. : 711-719

Springer Publishing Company

Access to resources Recommend Favorite

Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates

By Earnshaw S. R.   Graham C. N.   Ettinger B.   Amonkar M. M.   Lynch N. O.   Middelhoven H.  

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2517-2529

Informa Healthcare

Access to resources Recommend Favorite

Is Long‐Term Anti‐Osteoporotic Treatment Associated with Greater Risk of Cancer in People with Severe Vertebral Fractures? A Hospital‐Based Cohort Study

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 63, Iss. 11, 2015-11 ,pp. : 2418-2419

John Wiley & Sons Inc

Access to resources Recommend Favorite

What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?

By Miller P.   Derman R.  

Osteoporosis International, Vol. 21, Iss. 11, 2010-11 ,pp. : 1793-1802

Springer Publishing Company

Access to resources Recommend Favorite

Bone repair in osteoporotic bone: postmenopausal and cortisone-induced osteoporosis

By Cortet B.  

Osteoporosis International, Vol. 22, Iss. 6, 2011-06 ,pp. : 2007-2010

Springer Publishing Company

Access to resources Recommend Favorite